Prothena Corporation (PRTA)
| Bid | 8.5 |
| Market Cap | 469.64M |
| Revenue (ttm) | 135.16M |
| Net Income (ttm) | -122.31M |
| EPS (ttm) | -2.27 |
| PE Ratio (ttm) | -3.84 |
| Forward PE | -2.6 |
| Analyst | Buy |
| Ask | 10 |
| Volume | 1,524,700 |
| Avg. Volume (20D) | 493,968 |
| Open | 9.21 |
| Previous Close | 9.20 |
| Day's Range | 8.59 - 9.27 |
| 52-Week Range | 8.59 - 25.42 |
| Beta | 0.07 |
About PRTA
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease...
Analyst Forecast
According to 9 analyst ratings, the average rating for PRTA stock is "Buy." The 12-month stock price forecast is $55, which is an increase of 530.37% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Prothena Corporation plc (PRTA) Q4 2024 Earnings Call TranscriptProthena Corporation plc (NASDAQ:PRTA ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Mark Johnson - Vice President of Investor Relations Gene Kinney - President a...
